Blog

Learn about dilution buffers in antibody research, their composition, and applications in ELISA, Western blotting, and immunohistochemistry for reliable results.

Learn the difference between ADC biosimilars as cost-effective alternatives to reference drugs and ADC isotypes engineered for distinct therapeutic properties in cancer treatment.

Antibody production underpins biotech progress. Biointron explains traditional and recombinant methods that enable scalable, reliable antibody development.

Fully human antibodies reduce immunogenicity and improve safety. Biointron highlights their role in future therapies and the promise they hold for patients.

ADCs enhance in vivo research precision. Biointron explores how targeted payload delivery improves study accuracy and supports next-generation therapeutic design.

In vivo vs. in vitro antibody production each offers benefits and limits. Biointron compares approaches to guide reliable, scalable therapeutic development.

Discover the efficiency of AbDrop™ and HUGO-Ab™ for rapid, fully human antibody discovery using microfluidics and TurboKnockout® technology with results in as little as 3 months.

The 12th Immuno-Oncology Summit in Philadelphia spotlighted antibody therapeutics. Biointron shares event highlights driving progress in cancer immunotherapy.

Research-use-only biologics support early discovery. Biointron explains how RUO materials empower preclinical antibody development and accelerate translational progress.

Explore how bispecific antibodies (BsAbs) transform in vivo research by enhancing oncology, immunotherapy, and drug development through dual-targeting precision.

BIO Asia 2024 in Taiwan featured breakthroughs in biotech and antibodies. Biointron shares key takeaways that define trends in global biologics and innovation.

BIX 2024 in Seoul spotlighted biotech and antibody advances. Biointron reports event highlights shaping innovation across discovery, development, and therapeutics.